Guest Editorial The anatomy of my decision to take a PAUSE and explore life outside the cancer center director’s office February 24, 2023Vol.49 No.08By George J. Weiner
Guest Editorial ODAC clears a path for dostarlimab, a drug that may “beat the reaper” in locally advanced rectal cancer February 10, 2023Vol.49 No.06By Richard M. Goldberg
Guest Editorial A Super Bowl LVII challenge: It’s Chiefs/KU vs. Eagles/SKCC February 10, 2023Vol.49 No.06By Matthew Huesser and Christine Thomas
Guest Editorial Healing from gun violence in Asian America: What does love look like in a time of hate?天下太平 Peace under the celestial sky February 03, 2023Vol.49 No.05By Cevadne Lee
Guest Editorial NIH, NCI face devastating cuts in debt ceiling fight; We must rally for biomedical research January 27, 2023Vol.49 No.04By Lisa M. Coussens
Guest Editorial ODAC Confidential: The seven deadly sins sponsors commit again and again at FDA presentations January 20, 2023Vol.49 No.03By Mikkael A. Sekeres
Guest Editorial Ending cancer as we know it—for everyone—begins with the numbers January 13, 2023Vol.49 No.02By William L. Dahut
FreeGuest Editorial A New Year’s greeting from Ukraine January 06, 2023Vol.49 No.01By Andriy Beznosenko
FreeGuest Editorial S2302 Pragmatica-Lung Trial: Reaching more representative groups of patients with exciting clinical trials December 21, 2022Vol.48 No.46By Jhanelle E. Gray, Karen Reckamp, Mary Redman, Konstantin H. Dragnev, Ellen V. Sigal, Shakun Malik, Meg Mooney, James H. Doroshow and Charles D. Blanke
FreeGuest Editorial NCI’s Cancer Prevention-Interception Targeted Agent Discovery (CAP-IT) Program, a milestone in cancer prevention research December 21, 2022Vol.48 No.46By Margie Clapper
